Composition for inhibiting uric acid formation and application thereof

Abstract

The present invention relates to a composition for inhibiting the formation of uric acid and its application, and belongs to the technical field of inhibiting uric acid. A composition for inhibiting the formation of uric acid comprises the following components: olive extract, kudzu root extract, green tea extract, mulberry branch extract, modified curcumin, chicory extract and gardenia extract; the modified curcumin is prepared by curcumin, chitosan and p-hydroxycinnamaldehyde under a specific process. The present invention regulates the expression of transporter proteins through olive extract, kudzu root extract, green tea extract, mulberry branch extract, modified curcumin, chicory extract and gardenia extract, reduces the reabsorption of uric acid in the kidney, reduces the activity of xanthine oxidase, protects the kidney from damage, promotes and strengthens uric acid excretion, and other mechanisms work together to reduce the synthesis of uric acid and promote its excretion; the composition for inhibiting the formation of uric acid of the present invention is used in tea bags, effervescent tablets or oral liquids.

Description

Technical Field

[0001] The invention belongs to the technical field of inhibiting uric acid, and relates to a composition for inhibiting uric acid formation and application thereof. Background Art

[0002] Hyperuricemia is a common disease caused by purine metabolism disorders or insufficient uric acid excretion in the body. This condition is closely related to the occurrence and development of many diseases. In recent years, the incidence of hyperuricemia has shown an increasing trend year by year, which has attracted widespread attention in the medical community. Hyperuricemia is not only an independent disease, but is also often accompanied by a series of complications, which seriously threaten human health and quality of life. At present, although the drugs used in clinical treatment of hyperuricemia have certain therapeutic effects, these drugs often produce a series of side effects during use, which greatly limit their wide application in clinical treatment.

[0003] Curcumin is a natural active polyphenol monomer component extracted from traditional Chinese medicinal materials such as turmeric, zedoary turmeric, and turmeric. It has an orange-yellow appearance and a slightly bitter taste. It has a variety of physiological activities, including anti-inflammatory, antioxidant, anti-cancer and lipid-lowering properties. Recent studies have shown that the application of curcumin in cancer, diabetes, cardiovascular disease, neurodegenerative diseases, gastrointestinal irritation and uric acid reduction has been fully confirmed, and it has shown the advantage of no obvious toxicity in these applications. Supplementation of curcumin can effectively reduce the patient's uric acid concentration, thereby alleviating the symptoms of hyperuricemia to a certain extent. However, curcumin in natural extracts is sensitive to light and heat, has poor light resistance and heat resistance, and has disadvantages such as poor stability and low bioavailability, which greatly limit its potential in clinical applications. In addition, free curcumin exists at extremely low levels in the body. Due to its low water solubility, chemical instability and crystal structure, its bioavailability is low, which further limits the wide application of curcumin in the pharmaceutical field. Summary of the invention

[0004] The object of the present invention is to provide a composition for inhibiting the formation of uric acid and an application thereof. The present invention regulates the expression of transporter proteins through olive extract, kudzu root extract, green tea extract, mulberry branch extract, modified curcumin, chicory extract and gardenia extract, reduces the reabsorption of uric acid in the kidney, reduces the activity of xanthine oxidase (XOD), protects the kidney from damage, promotes and strengthens the excretion of uric acid, and reduces the synthesis of uric acid and promotes its excretion under the combined action of multiple mechanisms; the composition for inhibiting the formation of uric acid of the present invention is used in tea bags, effervescent tablets or oral liquids.

[0005] The purpose of the present invention can be achieved through the following technical solutions:

[0006] A composition for inhibiting uric acid formation, comprising the following components by weight:

[0007]

[0008] The composition further comprises the following components by weight: 1-2 parts by weight of monk fruit extract, 0.5-1 parts by weight of chrysanthemum extract, 0.2-1 parts by weight of liquorice extract, 0.2-1 parts by weight of astragalus extract, 1-2 parts by weight of jujube extract and 0.5-1.5 parts by weight of mulberry extract.

[0009] Luo Han Guo extract contains active ingredients such as triterpenoids and flavonoids, which have the effects of clearing heat and moistening the lungs, relieving cough and reducing phlegm. Its anti-inflammatory and antioxidant properties may help improve kidney function, thereby indirectly reducing the excretion of urinary protein.

[0010] Chrysanthemum extract is rich in flavonoids, volatile oils and other ingredients, and has the effects of clearing away heat and detoxifying, calming the liver and improving eyesight; chrysanthemum extract has certain anti-inflammatory and antioxidant effects, which can protect kidney cells and reduce inflammatory responses, which may help lower urine protein levels.

[0011] Glycyrrhizic acid in licorice extract has anti-inflammatory and immunomodulatory effects; moderate use of licorice extract can relieve kidney inflammation and reduce kidney damage, which may help reduce the excretion of urinary protein.

[0012] Astragalus extract contains active ingredients such as astragalus polysaccharides and flavonoids, which have the effects of enhancing immunity, anti-oxidation and anti-inflammatory. Astragalus extract can improve kidney function, reduce the excretion of urinary protein, and also help lower uric acid levels.

[0013] Jujube extract is rich in various vitamins, minerals and bioactive substances, and has the effects of tonifying the middle and replenishing qi, nourishing blood and calming the nerves; jujube extract can enhance the body's immunity, improve nutritional status, have a certain protective effect on the kidneys, and may help reduce the excretion of urinary protein.

[0014] Mulberry extract is rich in antioxidant ingredients such as anthocyanins and vitamin C, and has antioxidant, anti-inflammatory, and hypoglycemic effects. Mulberry extract can improve kidney function, reduce the excretion of urinary protein, and also help lower uric acid levels.

[0015] When the above ingredients are used in combination, their synergistic effect will more significantly improve kidney function, reduce urinary protein excretion, and help lower uric acid levels.

[0016] The present invention discloses a method for preparing the modified curcumin, comprising the following steps:

[0017] 1) after mixing deionized water and chitosan, adding curcumin and anhydrous ethanol, stirring and mixing, and then ultrasonically treating to obtain a premix;

[0018] 2) While stirring, slowly add p-hydroxycinnamaldehyde to the premix, stir at room temperature after the addition is complete, centrifuge to remove the supernatant, add deionized water to resuspend and wash the precipitate, centrifuge again, repeat three times, take the solid and freeze-dry it to obtain the product.

[0019] As a preferred technical solution of the present invention, in step 1), the stirring and mixing is stirring at a rotation speed of 2000-3000 r / min for 10-15 min.

[0020] As a preferred technical solution of the present invention, in step 1), the ultrasonic treatment is performed at a frequency of 1000-1200W for 30-45min.

[0021] As a preferred technical solution of the present invention, in step 2), the stirring time at room temperature is 24-30 hours.

[0022] As a preferred technical solution of the present invention, in the preparation of modified curcumin, the mass ratio of chitosan, deionized water, curcumin, anhydrous ethanol and p-hydroxycinnamaldehyde is 0.5-0.6:250-300:0.08-0.10:30-33:0.8-1.0.

[0023] The present invention discloses a method for preparing a composition for inhibiting uric acid formation, comprising the following steps:

[0024] The raw materials are weighed according to their weight, and the temperature is controlled while adding the materials while stirring. After the addition is completed, the materials are stirred again and allowed to stand to obtain a composition for inhibiting the formation of uric acid.

[0025] As a preferred technical solution of the present invention, in the preparation of the composition, the temperature of the temperature control is 26-32°C.

[0026] As a preferred technical solution of the present invention, in the preparation of the composition, the further stirring is stirring at a speed of 600-800 r / min for 30-45 min, and the standing time is 1-2 h.

[0027] The invention discloses an application of a composition for inhibiting the formation of uric acid. The application is to prepare the composition for inhibiting the formation of uric acid into a tea bag, an effervescent tablet or an oral liquid.

[0028] Beneficial effects of the present invention:

[0029] The present invention regulates the expression of transporter proteins through olive extract, kudzu root extract, green tea extract, mulberry branch extract, modified curcumin, chicory extract and gardenia extract, reduces the reabsorption of uric acid in the kidney, reduces the activity of xanthine oxidase (XOD), protects the kidney from damage, promotes and strengthens uric acid excretion, and other mechanisms, thereby reducing the synthesis of uric acid and promoting its excretion. DETAILED DESCRIPTION

[0030] In order to further illustrate the technical means and effects adopted by the present invention to achieve the predetermined invention purpose, the specific implementation methods, structures, features and effects of the present invention are described in detail below in combination with the embodiments.

[0031] Example 1

[0032] A composition for inhibiting uric acid formation comprises the following components by weight:

[0033]

[0034] Wherein, the preparation method of the modified curcumin comprises the following steps:

[0035] 1) after mixing deionized water and chitosan, adding curcumin and anhydrous ethanol, stirring and mixing, and then ultrasonically treating to obtain a premix;

[0036] 2) While stirring, slowly add p-hydroxycinnamaldehyde to the premix, stir at room temperature after the addition is complete, centrifuge to remove the supernatant, add deionized water to resuspend and wash the precipitate, centrifuge again, repeat three times, take the solid and freeze-dry it to obtain the product.

[0037] In step 1), the stirring and mixing is stirring at a rotation speed of 2000 r / min for 10 minutes; and the ultrasonic treatment is ultrasonic treatment at a frequency of 1000 W for 30 minutes.

[0038] In step 2), the stirring time at room temperature is 24 hours.

[0039] In the preparation of modified curcumin, the mass ratio of chitosan, deionized water, curcumin, anhydrous ethanol and p-hydroxycinnamaldehyde is 0.5:250:0.08:30:0.8.

[0040] A method for preparing a composition for inhibiting uric acid formation comprises the following steps:

[0041] The raw materials are weighed according to their weight, and the temperature is controlled while adding the materials while stirring. After the addition is completed, the materials are stirred again and allowed to stand to obtain a composition for inhibiting the formation of uric acid.

[0042] In the preparation of the composition, the temperature of the temperature control is 26°C.

[0043] In the preparation of the composition, the further stirring is stirring at a rotation speed of 600 r / min for 30 minutes, and the standing time is 1 hour.

[0044] Example 2

[0045] A composition for inhibiting uric acid formation comprises the following components by weight:

[0046]

[0047] Wherein, the preparation method of the modified curcumin comprises the following steps:

[0048] 1) after mixing deionized water and chitosan, adding curcumin and anhydrous ethanol, stirring and mixing, and then ultrasonically treating to obtain a premix;

[0049] 2) While stirring, slowly add p-hydroxycinnamaldehyde to the premix, stir at room temperature after the addition is complete, centrifuge to remove the supernatant, add deionized water to resuspend and wash the precipitate, centrifuge again, repeat three times, take the solid and freeze-dry it to obtain the product.

[0050] In step 1), the stirring and mixing is performed at a rotation speed of 2200 r / min for 11 min; and the ultrasonic treatment is performed at a frequency of 1040 W for 33 min.

[0051] In step 2), the stirring time at room temperature is 25 h.

[0052] In the preparation of modified curcumin, the mass ratio of chitosan, deionized water, curcumin, anhydrous ethanol and p-hydroxycinnamaldehyde is 0.52:260:0.08:30.6:0.8.

[0053] A method for preparing a composition for inhibiting uric acid formation comprises the following steps:

[0054] The raw materials are weighed according to their weight, and the temperature is controlled while adding the materials while stirring. After the addition is completed, the materials are stirred again and allowed to stand to obtain a composition for inhibiting the formation of uric acid.

[0055] In the preparation of the composition, the temperature of the temperature control is 27°C.

[0056] In the preparation of the composition, the further stirring is stirring at a rotation speed of 640 r / min for 33 minutes, and the standing time is 1.2 hours.

[0057] Example 3

[0058] A composition for inhibiting uric acid formation comprises the following components by weight:

[0059]

[0060]

[0061] Wherein, the preparation method of the modified curcumin comprises the following steps:

[0062] 1) after mixing deionized water and chitosan, adding curcumin and anhydrous ethanol, stirring and mixing, and then ultrasonically treating to obtain a premix;

[0063] 2) While stirring, slowly add p-hydroxycinnamaldehyde to the premix, stir at room temperature after the addition is complete, centrifuge to remove the supernatant, add deionized water to resuspend and wash the precipitate, centrifuge again, repeat three times, take the solid and freeze-dry it to obtain the product.

[0064] In step 1), the stirring and mixing is performed at a rotation speed of 2400 r / min for 12 min; and the ultrasonic treatment is performed at a frequency of 1080 W for 36 min.

[0065] In step 2), the stirring time at room temperature is 26 h.

[0066] In the preparation of modified curcumin, the mass ratio of chitosan, deionized water, curcumin, anhydrous ethanol and p-hydroxycinnamaldehyde is 0.54:270:0.08:31.2:0.8.

[0067] A method for preparing a composition for inhibiting uric acid formation comprises the following steps:

[0068] The raw materials are weighed according to their weight, and the temperature is controlled while adding the materials while stirring. After the addition is completed, the materials are stirred again and allowed to stand to obtain a composition for inhibiting the formation of uric acid.

[0069] In the preparation of the composition, the temperature of the temperature control is 28°C.

[0070] In the preparation of the composition, the further stirring is stirring at a rotation speed of 680 r / min for 36 minutes, and the standing time is 1.4 hours.

[0071] Example 4

[0072] A composition for inhibiting uric acid formation comprises the following components by weight:

[0073]

[0074]

[0075] Wherein, the preparation method of the modified curcumin comprises the following steps:

[0076] 1) after mixing deionized water and chitosan, adding curcumin and anhydrous ethanol, stirring and mixing, and then ultrasonically treating to obtain a premix;

[0077] 2) While stirring, slowly add p-hydroxycinnamaldehyde to the premix, stir at room temperature after the addition is complete, centrifuge to remove the supernatant, add deionized water to resuspend and wash the precipitate, centrifuge again, repeat three times, take the solid and freeze-dry it to obtain the product.

[0078] In step 1), the stirring and mixing is performed at a rotation speed of 2600 r / min for 13 min; and the ultrasonic treatment is performed at a frequency of 1120 W for 39 min.

[0079] In step 2), the stirring time at room temperature is 28 h.

[0080] In the preparation of modified curcumin, the mass ratio of chitosan, deionized water, curcumin, anhydrous ethanol and p-hydroxycinnamaldehyde is 0.56:280:0.09:31.8:0.9.

[0081] A method for preparing a composition for inhibiting uric acid formation comprises the following steps:

[0082] The raw materials are weighed according to their weight, and the temperature is controlled while adding the materials while stirring. After the addition is completed, the materials are stirred again and allowed to stand to obtain a composition for inhibiting the formation of uric acid.

[0083] In the preparation of the composition, the temperature of the temperature control is 30°C.

[0084] In the preparation of the composition, the further stirring is stirring at a rotation speed of 720 r / min for 39 minutes, and the standing time is 1.6 hours.

[0085] Example 5

[0086] A composition for inhibiting uric acid formation comprises the following components by weight:

[0087]

[0088] Wherein, the preparation method of the modified curcumin comprises the following steps:

[0089] 1) after mixing deionized water and chitosan, adding curcumin and anhydrous ethanol, stirring and mixing, and then ultrasonically treating to obtain a premix;

[0090] 2) While stirring, slowly add p-hydroxycinnamaldehyde to the premix, stir at room temperature after the addition is complete, centrifuge to remove the supernatant, add deionized water to resuspend and wash the precipitate, centrifuge again, repeat three times, take the solid and freeze-dry it to obtain the product.

[0091] In step 1), the stirring and mixing is performed at a rotation speed of 2800 r / min for 14 min; and the ultrasonic treatment is performed at a frequency of 1160 W for 42 min.

[0092] In step 2), the stirring time at room temperature is 29 h.

[0093] In the preparation of modified curcumin, the mass ratio of chitosan, deionized water, curcumin, anhydrous ethanol and p-hydroxycinnamaldehyde is 0.58:290:0.09:32.4:0.9.

[0094] A method for preparing a composition for inhibiting uric acid formation comprises the following steps:

[0095] The raw materials are weighed according to their weight, and the temperature is controlled while adding the materials while stirring. After the addition is completed, the materials are stirred again and allowed to stand to obtain a composition for inhibiting the formation of uric acid.

[0096] In the preparation of the composition, the temperature of the temperature control is 31°C.

[0097] In the preparation of the composition, the further stirring is stirring at a rotation speed of 760 r / min for 42 minutes, and the standing time is 1.8 hours.

[0098] Example 6

[0099] A composition for inhibiting uric acid formation comprises the following components by weight:

[0100]

[0101] Wherein, the preparation method of the modified curcumin comprises the following steps:

[0102] 1) after mixing deionized water and chitosan, adding curcumin and anhydrous ethanol, stirring and mixing, and then ultrasonically treating to obtain a premix;

[0103] 2) While stirring, slowly add p-hydroxycinnamaldehyde to the premix, stir at room temperature after the addition is complete, centrifuge to remove the supernatant, add deionized water to resuspend and wash the precipitate, centrifuge again, repeat three times, take the solid and freeze-dry it to obtain the product.

[0104] In step 1), the stirring and mixing is performed at a rotation speed of 3000 r / min for 15 min; and the ultrasonic treatment is performed at a frequency of 1200 W for 45 min.

[0105] In step 2), the stirring time at room temperature is 30 h.

[0106] In the preparation of modified curcumin, the mass ratio of chitosan, deionized water, curcumin, anhydrous ethanol and p-hydroxycinnamaldehyde is 0.6:300:0.10:33:1.0.

[0107] A method for preparing a composition for inhibiting uric acid formation comprises the following steps:

[0108] The raw materials are weighed according to their weight, and the temperature is controlled while adding the materials while stirring. After the addition is completed, the materials are stirred again and allowed to stand to obtain a composition for inhibiting the formation of uric acid.

[0109] In the preparation of the composition, the temperature of the temperature control is 32°C.

[0110] In the preparation of the composition, the further stirring is stirring at a speed of 800 r / min for 45 minutes, and the standing time is 2 hours.

[0111] Comparative Examples 1-4

[0112] Compared with Example 5, the difference between Comparative Examples 1-4 is that the amounts of olive extract, kudzu root extract, green tea extract and mulberry branch extract are as shown in Table 1, and the other components, preparation steps and parameters are the same.

[0113] Table 1 (Unit: parts by weight)

[0114] Olive Extract Pueraria root extract Green Tea Extract Mulberry Branch Extract Example 5 7 12 12 5.4 Comparative Example 1 0 14 14 8.4 Comparative Example 2 11 0 16 9.4 Comparative Example 3 11 16 0 9.4 Comparative Example 4 8.8 13.8 13.8 0

[0115] Comparative Example 5

[0116] Compared with Example 5, the difference of Comparative Example 5 is that, in step 1), deionized water, curcumin and anhydrous ethanol are subjected to ultrasonic treatment, chitosan is added and stirred and mixed to obtain a premix; in step 1), the stirring and mixing is stirring at a speed of 2800 r / min for 14 min; the ultrasonic treatment is ultrasonic treatment at a frequency of 1160 W for 42 min;

[0117] The remaining components, preparation steps and parameters were the same.

[0118] Comparative Example 6

[0119] Compared with Example 5, Comparative Example 6 is different in that chitosan is not added, and the other components, preparation steps and parameters are the same.

[0120] Comparative Example 7

[0121] Compared with Example 5, Comparative Example 7 is different in that cinnamaldehyde is used instead of p-hydroxycinnamaldehyde, and the other components, preparation steps and parameters are the same.

[0122] Comparative Example 8

[0123] Compared with Example 5, Comparative Example 8 is different in that p-hydroxycinnamaldehyde is not used, and the remaining components, preparation steps and parameters are the same.

[0124] Comparative Example 9

[0125] Compared with Example 5, Comparative Example 9 is different in that curcumin is used instead of modified curcumin, and the other components, preparation steps and parameters are the same.

[0126] The compositions prepared in Examples 1-6 and Comparative Examples 1-9 were tested as follows, and the test results are shown in Table 2.

[0127] After 3 days of adaptive feeding, SD rats were randomly divided into 18 groups, namely normal group, model group, positive drug group, Example 1-6 group, Comparative Example 1-9 group, 12 rats in each group. During the experiment, except for the normal group, the animals in the remaining groups were gavaged with adenine (100 mg / kg) and ethambutol (250 mg / kg) suspension (the solvent was 0.5% sodium carboxymethyl cellulose aqueous solution) every day, and the normal group was given the same volume of 0.5% sodium carboxymethyl cellulose aqueous solution for 23 days; from the beginning of modeling, 24h urine of rats in the normal group and model group was collected in a metabolic cage every 5 days, and the uric acid content in the urine was determined. If the uric acid content in the urine was significantly different between the normal group and the model group, the modeling was successful. The drug was given on the 5th day of modeling, and each group was gavaged with the composition prepared in the corresponding embodiment or comparative example, and the dosage was 1g / kg. The positive drug group was given 5 mg / kg of alopnivir every day, and the normal group and model group were given the same mass of pure water every day, with a dosage of 1 g / kg.

[0128] Determination of rat urine indicators: 1 day before the last administration, the 24-hour urine of each group of rats was collected and weighed using a metabolic cage, the uric acid content in the rat urine was determined, and the urine protein content in the last 24-hour urine of the rats was determined. The results are shown in Table 2.

[0129] Table 2

[0130]

[0131]

[0132] From the test results in Table 2, it can be seen that compared with Comparative Examples 1-9, the compositions prepared in Examples 1-6 of the present invention are significantly better than Comparative Examples 1-9; that is, the compositions prepared in the present invention can effectively inhibit the formation of uric acid and promote the excretion of uric acid. Through the analysis of Examples 1-6 and Comparative Examples 1-9 combined with Table 2, it can be seen that the active ingredients in the olive extract, such as piperine and luteolin, can inhibit the uric acid transporter URAT1, reduce the reabsorption of uric acid in the kidney, and reduce the activity of xanthine oxidase (XOD) in the liver, thereby reducing the production of uric acid; the kudzu root isoflavones in the kudzu root extract further reduce the production of uric acid and promote uric acid excretion by inhibiting the expression of XOD and GLUT9; the tea polyphenols and tea pigment compounds in the green tea extract act through a dual mechanism, inhibiting purine metabolic enzymes to reduce the production of uric acid and regulating uric acid transporters to increase the excretion of uric acid; the mulberry branch polysaccharide and RMP in the mulberry branch extract protect the kidney from damage by enhancing the expression of uric acid excretion-related protein ABCG2 and inhibiting the expression of renal fibrosis-related protein ColI; curcumin can promote the expression of renal cell uric acid transporter ABCG2 by activating nuclear factor κB, and also has the effect of protecting the kidney structure and inhibiting uric acid production.

[0133] Furthermore, chitosan is weakly alkaline, which can promote the ionization of hydrogen protons on the hydroxyl group of curcumin, combine through electrostatic action, self-aggregate to form nanoparticles or microparticles, protect curcumin, and form a chemical bond connection between the amino group and the aldehyde group of p-hydroxycinnamaldehyde to form a coating on curcumin, thereby further protecting it; in addition, since the para-position of p-hydroxycinnamaldehyde is an electron-pushing phenolic hydroxyl group, it can not only form a more stable compound with chitosan and curcumin through hydrogen bonds, coordination bonds and electrostatic adsorption, but also promote the inhibition strength of modified curcumin on XOD enzyme. Furthermore, the carbonyl groups on the curcumin and Schiff base structures can form hydrogen bonding forces with the amino acid residues on the XOD enzyme to form a stable chelating ligand structure, combined with the introduction of a hydrophobic benzene ring structure, so that it can stably exist in the hydrophobic environment of the XOD enzyme, and form a steric hindrance around the active center to prevent the substrate from interacting with the active center, thereby inhibiting the catalytic activity of the XOD enzyme and reducing the synthesis of uric acid.

[0134] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technical personnel in this field can make some changes or modify the technical contents disclosed above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any brief modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the technical solution of the present invention.

Claims

1. A composition for inhibiting uric acid formation, characterized in that: The components include the following by weight: Olive extract 4-8 parts by weight 8-13 parts by weight of Pueraria root extract Green tea extract 6-14 parts by weight 3-6 parts by weight of mulberry branch extract Modified curcumin 8-10 parts by weight Chicory extract 5-8 parts by weight 7-11 parts by weight of Gardenia jasminoides extract; The preparation method of the modified curcumin comprises the following steps: 1) After deionized water and chitosan are mixed, curcumin and anhydrous ethanol are added, stirred and mixed, and then ultrasonic treatment is performed to obtain a premix; 2) While stirring, slowly add p-hydroxycinnamaldehyde to the premix, stir at room temperature after the addition is complete, centrifuge to remove the supernatant, add deionized water to resuspend and wash the precipitate, centrifuge again, repeat three times, take the solid and freeze-dry it to obtain; In the preparation of modified curcumin, the mass ratio of chitosan, deionized water, curcumin, anhydrous ethanol and p-hydroxycinnamaldehyde is 0.5-0.6:250-300:0.08-0.10:30-33:0.8-1.

0.

2. A composition for inhibiting uric acid formation according to claim 1, characterized in that: In step 1), the stirring and mixing is performed at a rotation speed of 2000-3000 r / min for 10-15 min.

3. A composition for inhibiting uric acid formation according to claim 1, characterized in that: In step 1), the ultrasonic treatment is performed at a frequency of 1000-1200 W for 30-45 min.

4. A composition for inhibiting uric acid formation according to claim 1, characterized in that: In step 2), the stirring time at room temperature is 24-30 hours.

5. A composition for inhibiting uric acid formation according to claim 1, characterized in that: The method for preparing the composition for inhibiting uric acid formation comprises the following steps: The raw materials are weighed according to their weight, and the temperature is controlled while adding the materials while stirring. After the addition is completed, the materials are stirred again and allowed to stand to obtain a composition for inhibiting the formation of uric acid.

6. A composition for inhibiting uric acid formation according to claim 5, characterized in that: In the preparation of the composition, the temperature of the temperature control is 26-32° C.; the stirring is stirring at a speed of 600-800 r / min for 30-45 min, and the standing time is 1-2 h.

7. A composition for inhibiting uric acid formation according to claim 1, characterized in that: The composition further comprises the following components by weight: 1-2 parts by weight of monk fruit extract, 0.5-1 parts by weight of chrysanthemum extract, 0.2-1 parts by weight of liquorice extract, 0.2-1 parts by weight of astragalus extract, 1-2 parts by weight of jujube extract and 0.5-1.5 parts by weight of mulberry extract.

8. Use of the composition for inhibiting uric acid formation according to any one of claims 1 to 7, characterized in that: The application is to prepare the composition for inhibiting the formation of uric acid into tea bags, effervescent tablets or oral liquid.

Images